TLR6 and neoplasm: A recent study has documented that versican can activate tumour-infiltrating myeloid cells through TLR2 and its coreceptors TLR6 and CD14 and elicit the production of proinflammatory cytokines including TNF-α that enhance tumour metastasis [51].